SEC Form 4 · accession 0000880771-16-000217
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Dec 21, 2016
Accepted (ET)
Dec 22, 2016 · 6:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 21, 2016 | M | 23,099 | $1.81 | A | 109,883 | D | |
| Common Stock | Dec 21, 2016 | S | 23,099 | $10.6096 | D | 86,784 | D | |
| Common Stock | Dec 21, 2016 | M | 40,000 | $1.81 | A | 126,784 | D | |
| Common Stock | Dec 21, 2016 | S | 40,000 | $10.5387 | D | 86,784 | D | |
| Common Stock | Dec 22, 2016 | M | 6,901 | $1.81 | A | 93,685 | D | |
| Common Stock | Dec 22, 2016 | S | 6,901 | $10.3967 | D | 86,784 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $1.81 | Dec 21, 2016 | M | 23,099 | D | — | Mar 18, 2018 | Common Stock | 23,099 | 86,901 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $1.81 | Dec 21, 2016 | M | 40,000 | D | — | Mar 18, 2018 | Common Stock | 40,000 | 46,901 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $1.81 | Dec 22, 2016 | M | 6,901 | D | — | Mar 18, 2018 | Common Stock | 6,901 | 40,000 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F31/36th of such shares will vest on June 1, 2010 and 1/36th will vest monthly thereafter over a three-year period, provided the reporting person remains employed by the Company.